ホーム
マーケット
チャート&アイデア
Algo
ニュース
Store
ブローカー
ダウンロード
経済指標カレンダー
取引シグナル
Webターミナル
「
/
」を入力して検索:@user、$symbol
検索
ログイン
アカウントを作成
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
GLMD
#4054
Galmed Pharmaceuticals Ltd.
0.6
1
-7.58%
セクター:
ベース:
利益通貨:
日中レンジ
1年のレンジ
1日の変化
-7.58%
月次変化
-28.24%
6か月変化
-56.74%
1年の変化
-72.27%
以前の終値
0.6
6
Open
0.6
1
Bid
Ask
Low
0.6
1
High
0.6
1
ボリューム
2
マーケット
株
ヘルスケア
GLMD
Open full chart
Financials
Overview
明細書
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
1.65 M
2.35 M
Valuation ratios
Enterprise value
577.63 K
—
Price to earnings ratio
0.39
—
Price to sales ratio
—
—
Price to cash flow ratio
0.5
—
Price to book ratio
0.18
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.19
-0.85
Return on equity %
-0.21
-1.02
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
7.42
23.13
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.05
0.16
Long term debt to total equity ratio
0.05
0.19
Per share metrics
Operating cash flow per share
-3.71
-105.21
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
12.78
411.18
Net current asset value per share
17.32
443.93
Tangible book value per share
17.54
396.94
Working capital per share
14.99
364.51
Book value per share
17.54
396.94
ニュース
Galmed Pharmaceuticals 4 Mart’ta özel hissedar toplantısı düzenleyecek
Galmed Pharmaceuticals schedules special shareholder meeting for March 4
Galmed Pharmaceuticals Nasdaq’tan minimum teklif fiyatı bildirimi aldı
Galmed Pharmaceuticals receives Nasdaq minimum bid price notice
Galmed, Aramchol’un karaciğer kanserindeki potansiyeline ilişkin veri sunacak
Galmed to present data on Aramchol’s potential in liver cancer
Galmed hissesi MASH kombinasyon tedavisi için patent alımı sonrası yükseldi
Galmed stock rises after patent grant for MASH combo therapy
Galmed, Güney Kore’de kombinasyon tedavisi için patent aldı
Galmed receives patent for combination therapy in South Korea
Galmed Pharmaceuticals hisseleri CEO’nun iyimser görünümüyle yükseldi
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook